Therachon

📍 4051 Basel, Switzerland🗓 Founded 2014👥 3 employees💰 Last funded Sep 2016
Biotechnology🌐 therachon.com
Website LinkedIn
Therachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions for which there is significant unmet medical need. We are currently advancing a pipeline of therapeutics focused on rare gastrointestinal and musculoskeletal disorders and conditions. Our lead product candidate, apraglutide, is a second generation, potentially best-in-class, synthetic peptide analog of glucagon-like peptide-2, or GLP-2, that is being evaluated in two Phase 2 clinical trials for the treatment of patients with short bowel syndrome, or SBS, a malabsorption disorder caused by the loss of functional small intestine. Our second product candidate, TA-46, has completed a Phase 1 clinical trial and is designed to address the root molecular cause of achondroplasia, a rare genetic condition and the most common form of short-limbed dwarfism in humans. View our social media community guidelines here: http://bit.ly/2TdB4Vm.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2014
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in Therachon?
Therachon has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Therachon last raise funding?
The most recent investment in Therachon recorded on gritt.io was in September 2016.
When was Therachon founded?
Therachon was founded in 2014.
What industry is Therachon in?
Therachon operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Therachon based?
Therachon is headquartered in 4051 Basel, Switzerland.